MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

doi:10.1182/blood-2012-12-473702

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Blood - 10 Oct 2013

Xu-Monette Zijun Y, Møller Michael B, Tzankov Alexander, Montes-Moreno Santiago, Hu Wenwei, Manyam Ganiraju C, Kristensen Louise, Fan Lei, Visco Carlo, Dybkaer Karen, Chiu April, Tam Wayne, Zu Youli, Bhagat Govind, Richards Kristy L, Hsi Eric D, Choi William W L, van Krieken J Han, Huang Qin, Huh Jooryung, Ai Weiyun, Ponzoni Maurilio, Ferreri Andrés J M, Wu Lin, Zhao Xiaoying, Bueso-Ramos Carlos E, Wang Sa A, Go Ronald S, Li Yong, Winter Jane N, Piris Miguel A, Medeiros L Jeffrey, Young Ken H

Abstract excerpt

MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In a p53 genetically-defined large cohort of de novo DLBCL patients treated with rituximab, cycloph...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Immunologic Factors

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 23982177
DOI: 10.1182/blood-2012-12-473702
PMCID: PMC3952598

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23982177-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.PMID 23982177Read ↗

The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.Semantic proximity Read ↗

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Semantic proximity Read ↗

Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer CellsSemantic proximity Read ↗

TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.Semantic proximity Read ↗

Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.Semantic proximity Read ↗

p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.Semantic proximity Read ↗

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.